Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2005
12/29/2005US20050287530 TCL-1b gene and protein and related methods and compositions
12/29/2005US20050287521 Oligonucleotides from sequences coding for the surface component of ptlv envelope proteins and uses thereof
12/29/2005US20050287176 Dna sequences that encode antigens, cloning expression proteins serological diagnosis of canine leishmaniosis and proteins with Chemical intermediates
12/29/2005US20050287175 modulating fusion between a lysosome and an endosome that carries the toxin in the cell; locally co-administering a toxin and a lysosome-endosome fusion inhibitor to a group of muscles of the patient in need thereof
12/29/2005US20050287174 Immunizing against HIV infection
12/29/2005US20050287172 Influenza hemagglutinin and neuraminidase variants
12/29/2005US20050287171 bovine viral diarrhea virus; point mutations; glycoproteins; RNAse inhibition
12/29/2005US20050287170 Subunit vaccine against West Nile viral infection
12/29/2005US20050287169 Methods of use of genes of pyridoxal 5'-phosphate biosynthesis in Bacillus subtilis: avirulent strains for vaccines, and methods for identification of antibacterial agents
12/29/2005US20050287168 Recombinant spores
12/29/2005US20050287167 Polycistronic HIV vector constructs
12/29/2005US20050287166 Malarial pre-erythrocytic stage polypeptide molecules
12/29/2005US20050287165 Meningococcal antigens
12/29/2005US20050287164 Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections
12/29/2005US20050287163 Mycoplasma polypeptides
12/29/2005US20050287162 Recombinant fowlpox virus
12/29/2005US20050287161 Vaccine
12/29/2005US20050287160 Useful for treatment and prevention of prostate cancer, especially when associated with bone metastases; also a cytotoxic T lymphocyte that specifically recognizes complex of HLA-A24 antigen and the cancer antigen peptide
12/29/2005US20050287159 Treatment methods for eotaxin mediated inflammatory conditons
12/29/2005US20050287158 The p65 subunit of nf-kb for the radiosensitization of cells
12/29/2005US20050287157 Dry formulation for transcutaneous immunization
12/29/2005US20050287156 Novel amine-based adjuvant
12/29/2005US20050287155 Active agent has been modified by attachment of cell membrane-impermeabilizing group so that, if active agent so modified is cleaved from conjugate in blood plasma instead of inside target cell, the cell membrane-impermeabilizing group prevents or limits entry of modified active agent into cells
12/29/2005US20050287154 Autophilic antibodies and method of making and using same
12/29/2005US20050287152 Administering CTLA-4, tumor necrosis factor inhibitors, and immunogens
12/29/2005US20050287151 Secreted protein therapeutics and uses thereof
12/29/2005US20050287150 Antibodies against Clostridium difficile toxins and uses thereof
12/29/2005US20050287149 Human monoclonal antibodies against bacillus anthracis protective antigen
12/29/2005US20050287148 Monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
12/29/2005US20050287147 Cancer-linked gene as target for chemotherapy
12/29/2005US20050287146 Method of inhibiting Candida-related infections using donor selected or donor stimulated immunoglobulin compositions
12/29/2005US20050287145 Compositions and methods for producing vascular occlusion
12/29/2005US20050287144 For the modulation of signal activities controlled by NF-kappa B-inducing kinase (NIK); cancer , rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, asthma, cardiac infarct, Alzheimer's disease, or atherosclerosis
12/29/2005US20050287143 antibodies against such VEGFs, which may be used to inhibit their action, for example, to inhibit the growth of tumors, to treat diabetic retinopathy, rheumatoid arthritis and psoriasis
12/29/2005US20050287141 Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
12/29/2005US20050287140 Antibodies to angiogenesis inhibiting domains of CD148
12/29/2005US20050287139 Wound healing
12/29/2005US20050287138 CCR4-specific antibody composition
12/29/2005US20050287137 Novel composition
12/29/2005US20050287136 human cytotoxic T-lymphocyte antigen 4 (CTLA-4); heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4; administering an antibody or antigen-binding portion to treat a tumor
12/29/2005US20050287129 Vectors and methods for long-term immune evasion to prolong transplant viability
12/29/2005US20050287123 DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
12/29/2005US20050287118 Bacterial plasmid with immunological adjuvant function and uses thereof
12/29/2005US20050287117 Vaccine enhancing the protective immunity to hepatitis c virus using plasmid dna and recombinant adenovirus
12/29/2005US20050287116 Use in suicide gene therapy of cancer cells and producing immunotoxins; infecting the cell with an adenovirus produced by a packaging cell line, where an adenoviral vector of a promoter is linked to a nucleic acid encoding the A subunit of diphtheria toxin A or Pseudomonas Exotoxin A, mutated EF-2 gene
12/29/2005US20050287072 Administering a conjugate of a biocompatible entity and a light-generating moiety; and measuring photon emission through an opaque tissue of said mammalian subject from the light-generating moiety; used for tracking the progression of infection
12/29/2005US20050287068 Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
12/29/2005US20050287066 Anti-rat angiotensin I-converting enzyme (ACE, CD143) monoclonal antibodies and uses thereof
12/29/2005DE102004022574A1 Pharmaceutical formulation, for use in inflammatory disorders, identifies the rabies virus protein P as an interferon antagonist with substitution of the P-coded nucleic acid sequence
12/29/2005CA2847677A1 Methods for treating conditions associated with masp-2 dependent complement activation
12/29/2005CA2573144A1 Methods for treating conditions associated with masp-2 dependent complement activation
12/29/2005CA2572171A1 Use of dna molecule as vaccine adjuvant
12/29/2005CA2570508A1 Preparation of protective antigen from bacillus anthracis
12/29/2005CA2570392A1 Peptide vaccine for cancer therapy
12/29/2005CA2570271A1 Method of enhancing the immune response to a vaccine
12/29/2005CA2570218A1 Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
12/29/2005CA2570130A1 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof
12/29/2005CA2570034A1 Diagnosis and treatment of siglec-6 associated diseases
12/29/2005CA2570017A1 Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
12/29/2005CA2568570A1 Method of treating granuloma annulare or sarcoid
12/29/2005CA2567692A1 Therapeutic reprogramming, hybrid stem cells and maturation
12/29/2005CA2567686A1 Use of vegf inhibitors for the treatment of human cancer
12/29/2005CA2567129A1 Antibodies against human interleukin-13 and uses therefor
12/29/2005CA2566620A1 Vaccine against hpv16 and hpv18 and at least another hpv type slected from hpv 31, 45 or 52
12/28/2005EP1609865A2 Hepatitis B virus (HBV) variants
12/28/2005EP1609864A2 Use of neuronal apoptosis inhibitor protein (NAIP)
12/28/2005EP1609863A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/28/2005EP1608967A2 Compositions and methods for the diagnosis and treatment of tumor
12/28/2005EP1608767A2 Optimized expression of hpv 31 l1 in yeast
12/28/2005EP1608756A2 Staphylococcus epidermidis antigens
12/28/2005EP1608730A2 Truncated baff receptors
12/28/2005EP1608683A1 Antibodies directed against hepatitis c virus e1e2 complex, compositions of hcv particles, and pharmaceutical compositions
12/28/2005EP1608676A2 Nontypeable haemophilus influenzae virulence factors
12/28/2005EP1608675A2 Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use
12/28/2005EP1608404A2 Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (gitr or tnfrsf18)
12/28/2005EP1608403A2 Immunostimulatory nucleic acid oil-in-water formulations for topical application
12/28/2005EP1608402A1 Improved vaccines
12/28/2005EP1608401A1 Use of alum and a th1 immune response inducing adjuvant for enhancing immune respones
12/28/2005EP1608399A2 Ligands for tgf--beta binding proteins and uses thereof
12/28/2005EP1608393A2 Ebola peptides and immunogenic compositions containing same
12/28/2005EP1608391A2 Composition for inducing of immunotolerance
12/28/2005EP1608383A1 A formulation comprising a bacterial strain
12/28/2005EP1608369A2 Use of organic compounds for immunopotentiation
12/28/2005EP1608321A2 Cytokine-expressing cellular vaccine combinations
12/28/2005EP1608316A2 Methods and compositions for treating and preventing inflammatory conditions
12/28/2005EP1608315A2 Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
12/28/2005EP1608312A2 Methods for obtaining colonization factors from bacterial strains
12/28/2005EP1608307A2 An antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
12/28/2005EP1608255A2 Breast endothelial cell expression patterns
12/28/2005EP1427403B1 Valproic acid for the treatment of breast cancer, colon cancer, head and neck cancer, small cell lung carcinoma and cancer of the blood cells in combination with irradiation
12/28/2005EP1335987B1 Modified vaccinia ankara virus variant
12/28/2005EP1317489B1 A mixture of non-sulfated fucose-based oligosaccharides, a cosmetic or pharmaceutical composition comprising said mixture and its use in cosmetics or pharmacy
12/28/2005EP1274454B1 Methods and compositions for eliciting an immune response
12/28/2005EP1156811B1 Copper agonist that binds on the copper binding site of amyloid precursor protein (app) and/or exerts an inhibiting effect on the release of amyloid-beta-peptide
12/28/2005EP1135158B1 Enhanced vaccines based on chimeric immunoglobulin e peptides
12/28/2005EP1123114B1 Virus-like particles for the induction of autoantibodies
12/28/2005EP1073683B1 G-csf receptor agonist antibodies and screening method therefor
12/28/2005EP1025227B1 Human toll homologues
12/28/2005EP1021544B1 Chimeric vaccine against tick-borne encephalitis virus
12/28/2005EP0971959B1 Humanized antibodies and methods for forming humanized antibodies
1 ... 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 ... 1823